Citations 1
Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Plummer, Elizabeth Ruth, Cook, Natalie , Melear, Jason M., Redfern, Charles H., Chung, Ki Y. , Haddad, Tufia C. , Goddemeier, Thomas, Arkenau, Hendrik‐Tobias , Spira, Alexander I. , Shapiro, Geoffrey I. , Ramalingam, Suresh S. , Wesolowski, Robert , Falk, Martin H., Dean, Emma
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e21048-e21048
